Studying the Effects of Atorvastatin on the Arterial Performance of Ovary and Androgen Level of Blood Among Those Suffering from Polycystic Ovary Syndrome

SANEH, AZADEH AKBARI; Akbari, Maryam; Almasi, Alireza; Naderi, Zahra; KOUHPAYEZADEH, JALIL; Pourali, R; HOSSINZADEH, ZOHREH

doi:10.13005/bpj/1046

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study selection process was plotted in Figure 1. Eighty three potentially relevant articles were identified from the initial searches, but only 9 studies [15,19,20,[27][28][29][30][31][32] satisfying the inclusion Chen and Zheng Medicine (2021) 100:24 www.md-journal.com…”

Section: Description Of Included Studiesmentioning

confidence: 99%

“…[19] The maintenance doses of atorvastatin were 20 or 40 mg/day. PCOS patients in 2 studies [19,31] received atorvastatin 40 mg/day for 6 weeks. The treatment durations varied from 6 weeks to 6 months.…”

Section: Tablementioning

confidence: 99%

“…The risk of individual study bias was presented in Figure 2, 4 articles showed low risk of bias, [15,19,20,32] and 5 articles showed unclear risk of bias. [27][28][29][30][31] As shown in Figure 3, the funnel shape according to the fasting glucose concentration was almost symmetrical, which also indicated that there was no potential publication bias.…”

Section: Risk Of Biasmentioning

confidence: 99%

“…Eight trials [15,19,20,[27][28][29]31,32] involving a total of 356 patients measured the fasting glucose concentration (179 receiving atorvastatin therapy and 177 receiving placebo). As shown in Figure 4A, the RE model was used because significant heterogeneity between studies for the 2 groups was observed (P = .07, I 2 = 43%).…”

Section: Fasting Glucose Concentrationmentioning

confidence: 99%

“…Seven trials [19,20,[27][28][29][30][31] involving 332 patients measured the BMI. As shown in Figure 5B, the fixed-effect model was used because insignificant heterogeneity between studies for the two groups was observed (P = .78, I 2 = 0%).…”

Section: Bmi Valuementioning

confidence: 99%

See 4 more Smart Citations

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Chen¹,

Zheng²

2021

Medicine

View full text Add to dashboard Cite

Background: Atorvastatin treatment has been suggested as a therapeutic method for women with polycystic ovary syndrome (PCOS) in many clinical studies. Nonetheless, the effects of atorvastatin on insulin resistance in PCOS patients still remain controversial. Objective: The aim of this report was to evaluate the effects of atorvastatin therapy on the insulin resistance in the treatment of PCOS compared to that of placebo, in order to confer a reference for clinical practice. Methods: Randomized controlled trials (RCTs) of atorvastatin for PCOS published up to August, 2020 were searched. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated, and heterogeneity was measured by the I 2 test. Sensitivity analysis was also carried out. The outcomes of interest were as follows: fasting glucose concentration, fasting insulin level, homeostasis model assessment of insulin resistance (HOMA-IR) or body mass index (BMI) value. Results: Nine RCTs with 406 participants were included. The difference of fasting glucose concentration in PCOS patients between atorvastatin group and placebo group was not statistically significant (8 trials; SMD −0.06, 95% CI −0.31 to 0.20, P = .66). PCOS patients in atorvastatin group had lower fasting insulin level than those in placebo group (7 trials; SMD −1.84, 95% CI −3.06 to −0.62, P < .003). The homeostasis model assessment of insulin resistance (HOMA-IR) value showed significant decrease in the atorvastatin therapy compared to placebo (6 trials; SMD −4.12, 95% CI −6.00 to −2.23, P < .0001). In contrast to placebo, atorvastatin therapy did not decrease the BMI value significantly in PCOS patients (7 trials; SMD 0.12, 95% CI −0.07 to 0.31, P = .22). Conclusions: Atorvastatin therapy can reduce insulin resistance in the treatment of patients with PCOS. In addition, further large-sample, multi-center RCTs are needed to identify these findings.

show abstract

Section: Description Of Included Studiesmentioning

confidence: 99%

Section: Tablementioning

confidence: 99%

Section: Risk Of Biasmentioning

confidence: 99%

Section: Fasting Glucose Concentrationmentioning

confidence: 99%

Section: Bmi Valuementioning

confidence: 99%

See 3 more Smart Citations

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Chen¹,

Zheng²

2021

Medicine

View full text Add to dashboard Cite

show abstract

Effect of atorvastatin on testosterone levels

Shawish

Bagheri

Musini

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis

Hao,

Zhang,

Meng

2023

Medicine

View full text Add to dashboard Cite

Background: The optimal drug for treatment with polycystic ovary syndrome (PCOS) was in debate. We did this network meta-analysis to assess the efficacy and safety of different drugs for reducing testosterone levels in women with PCOS. Methods: We searched studies from inception until January 10, 2023, through PubMed, Embase, and Cochrane Library database. All studies comparing different drugs for reducing testosterone levels in women with polycystic ovary syndrome were included in this network meta-analysis. Outcomes were total testosterone levels, free testosterone levels, and withdraw due to adverse events. We calculated the surface under the cumulative ranking curve (SUCRA) for each treatment. Results: Finally, a total of 13 studies were finally included in this network meta-analysis. In head-to-head comparison, atorvastatin (WMD −3.1, 95% CrI: −3.7 to −2.5), metformin (WMD −2.6, 95% CrI: −3.5 to −1.6), metformin + simvastatin (WMD −2.8, 95% CrI: −4.1 to −1.5), simvastatin (WMD −2.7, 95% CrI: −4.2 to −1.3), spironolactone (WMD −3.1, 95% CrI: −4.3 to −1.9), spironolactone + metformin (WMD −3.2, 95% CrI: −4.5 to −2.0) were all more effective than the placebo, and the difference was statistically significant (P < .05). The SUCRA shows that spironolactone + metformin ranked first (SUCRA, 85.0%), Atorvastatin ranked second (SUCRA, 77.7%), Spironolactone ranked third (SUCRA, 77.2%), and metformin + simvastatin ranked the fourth. The SUCRA of different drugs for free testosterone levels shows that atorvastatin ranked first (SUCRA, 75.0%), spironolactone + metformin ranked second (SUCRA, 5.3%), metformin + simvastain ranked third (SUCRA, 62.6%), and spironolactone ranked the fourth (SUCRA, 56.4%). No statistically significant differences were found between the 2 treatment groups for withdrawn due to adverse events (P > .05). Conclusions: Considering the network meta-analysis and rankings, atorvastatin was recommended to be the optimal drug for treatment PCOS. However, the optimal dose of atorvastatin was unknown and should be verified by more randomized controlled trials.

show abstract

Studying the Effects of Atorvastatin on the Arterial Performance of Ovary and Androgen Level of Blood Among Those Suffering from Polycystic Ovary Syndrome

Cited by 3 publications

References 0 publications

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome

Effect of atorvastatin on testosterone levels

Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis

Contact Info

Product

Resources

About